Dispatch Bio shared a post on X:
“We’re pleased to announce the FDA clearance of the IND for DISP-10, enabling us to initiate a Ph1 clinical study in patients with solid tumors. Designed for broad applicability, DISP-10 has the potential to expand into multiple solid tumor indications.
Parker Institute for Cancer Immunotherapy shared this post, adding:
“Congrats to the team at PICI-founded company Dispatch Bio for FDA clearance of their IND application for DISP-10. This is an exciting milestone as they are one step closer to helping patients with multiple solid tumor indications.”
More posts about Parker Institute for Cancer Immunotherapy.